DE60235955D1 - Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen - Google Patents

Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen

Info

Publication number
DE60235955D1
DE60235955D1 DE60235955T DE60235955T DE60235955D1 DE 60235955 D1 DE60235955 D1 DE 60235955D1 DE 60235955 T DE60235955 T DE 60235955T DE 60235955 T DE60235955 T DE 60235955T DE 60235955 D1 DE60235955 D1 DE 60235955D1
Authority
DE
Germany
Prior art keywords
methods
compositions
cytokines
administration
superoxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235955T
Other languages
English (en)
Inventor
Daniela Salvemini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metaphore Pharmaceuticals Inc
Original Assignee
Metaphore Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metaphore Pharmaceuticals Inc filed Critical Metaphore Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60235955D1 publication Critical patent/DE60235955D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60235955T 2001-01-05 2002-01-03 Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen Expired - Lifetime DE60235955D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26012001P 2001-01-05 2001-01-05
PCT/US2002/000036 WO2002053142A2 (en) 2001-01-05 2002-01-03 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines

Publications (1)

Publication Number Publication Date
DE60235955D1 true DE60235955D1 (de) 2010-05-27

Family

ID=22987847

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60235955T Expired - Lifetime DE60235955D1 (de) 2001-01-05 2002-01-03 Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen

Country Status (7)

Country Link
US (1) US20050175580A1 (de)
EP (1) EP1347773B1 (de)
JP (1) JP4331939B2 (de)
AT (1) ATE464061T1 (de)
AU (1) AU2002241807A1 (de)
DE (1) DE60235955D1 (de)
WO (1) WO2002053142A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2056675T (pt) 2006-10-12 2019-05-09 Galera Labs Llc Métodos de tratamento da mucosite oral
US20110009416A1 (en) * 2009-07-07 2011-01-13 Sepracor Inc. PH INDEPENDENT FORMULATIONS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-DIHYDRO-5H-PYRROLO[3,4-b]PYRAZINE
EP2760874A4 (de) * 2011-09-26 2015-04-08 Galera Therapeutics Llc Verfahren zur behandlung von erkrankungen
EA201890471A1 (ru) 2015-08-11 2018-10-31 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комплексные соединения, содержащие макроциклическое кольцо пентаазы, обладающие пероральной биодоступностью
CN109906081A (zh) * 2016-09-01 2019-06-18 加莱拉实验室有限责任公司 利用五氮杂大环络合物和抗坏血酸类化合物的联合癌症疗法
US11246950B2 (en) 2017-04-13 2022-02-15 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2265387A (en) * 1940-03-11 1941-12-09 John H Mcmillin Nasal pack
US2493326A (en) * 1949-03-01 1950-01-03 John H Trinder Tampon for control of intractable nasal hemorrhages
US2847997A (en) * 1956-01-13 1958-08-19 James J Tibone Catheter
US3049125A (en) * 1960-03-28 1962-08-14 Kriwkowitsch George Nose packing device
US3420237A (en) * 1966-09-02 1969-01-07 Martha K Fortay Process and article for the treatment of severe epistaxis
GB1340788A (en) * 1971-02-04 1974-01-30 Matburn Holdings Ltd Nasal tampons
US4044793A (en) * 1975-08-25 1977-08-30 Shiley Laboratories, Inc. Relief valve
US4338941A (en) * 1980-09-10 1982-07-13 Payton Hugh W Apparatus for arresting posterior nosebleeds
US4364392A (en) * 1980-12-04 1982-12-21 Wisconsin Alumni Research Foundation Detachable balloon catheter
US4638803A (en) * 1982-09-30 1987-01-27 Rand Robert W Medical apparatus for inducing scar tissue formation in a body
US4619261A (en) * 1984-08-09 1986-10-28 Frederico Guerriero Hydrostatic pressure device for bleeding control through an inflatable, stitchable and retrievable balloon-net system
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
US4832680A (en) * 1986-07-03 1989-05-23 C.R. Bard, Inc. Apparatus for hypodermically implanting a genitourinary prosthesis
US4686962A (en) * 1986-07-03 1987-08-18 Habley Medical Technology Corporation Disposable cartridge assembly for hypodermically implanting a genitourinary prosthesis
US5192788A (en) * 1988-05-23 1993-03-09 Georgia State University Foundation, Inc. Porphyrin antiviral compositions
US4883465A (en) * 1988-05-24 1989-11-28 Brennan H George Nasal tampon and method for using
US5224497A (en) * 1988-07-06 1993-07-06 Ehlers Robert L Method of removing diverticula in the colon
US4950280A (en) * 1988-08-02 1990-08-21 Brennan H George Nasal tampon having a counter weight
US5100385A (en) * 1989-01-27 1992-03-31 C. R. Bard, Inc. Fast purge balloon dilatation catheter
AU640675B2 (en) * 1989-06-28 1993-09-02 Zkz Science Corp. Balloon tamponade devices and methods for their placement
US5061274A (en) * 1989-12-04 1991-10-29 Kensey Nash Corporation Plug device for sealing openings and method of use
CA2072934C (en) * 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5176692A (en) * 1991-12-09 1993-01-05 Wilk Peter J Method and surgical instrument for repairing hernia
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5545721A (en) * 1992-12-21 1996-08-13 Ophidian Pharmaceuticals, Inc. Conjugates for the prevention and treatment of sepsis
US5312435A (en) * 1993-05-17 1994-05-17 Kensey Nash Corporation Fail predictable, reinforced anchor for hemostatic puncture closure
US5486195A (en) * 1993-07-26 1996-01-23 Myers; Gene Method and apparatus for arteriotomy closure
TW252045B (de) * 1993-10-07 1995-07-21 Allan L Goldstein
US5545176A (en) * 1994-05-31 1996-08-13 Murtfeldt; Robert L. Wound dilatation device
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5645566A (en) * 1995-09-15 1997-07-08 Sub Q Inc. Apparatus and method for percutaneous sealing of blood vessel punctures
US5707355A (en) * 1995-11-15 1998-01-13 Zimmon Science Corporation Apparatus and method for the treatment of esophageal varices and mucosal neoplasms
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
JP2000507929A (ja) * 1996-03-13 2000-06-27 モンサント カンパニー ジスムタチンスーパーオキシドの触媒として有効な窒素含有大環状化合物配位子を持つ鉄錯体
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity

Also Published As

Publication number Publication date
JP4331939B2 (ja) 2009-09-16
EP1347773A2 (de) 2003-10-01
WO2002053142A3 (en) 2002-12-27
US20050175580A1 (en) 2005-08-11
ATE464061T1 (de) 2010-04-15
EP1347773B1 (de) 2010-04-14
JP2004517113A (ja) 2004-06-10
WO2002053142A2 (en) 2002-07-11
AU2002241807A1 (en) 2002-07-16

Similar Documents

Publication Publication Date Title
ES2207830T3 (es) Conjugados de polietilenglicol-interferon alfa para la terapia de infecciones.
ATE497775T1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
PL372294A1 (en) Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
BRPI0414045A (pt) administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c
CY1109216T1 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
RU94022480A (ru) Способ лечения гепатита, композиция, усиливающая ин виво инактивацию вируса гепатита с, препарат для лечения гепатита с
DE60132343D1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
HUP0102441A2 (hu) Megváltozott interferon-antagonista aktivitással rendelkező, legyengített negatívszálú vírusok vakcinaként és gyógyszerként való alkalmazásra
ATE539744T1 (de) Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
IL159087A0 (en) Bridged bicyclic compounds and pharmaceutical compositions containing the same
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
MY141594A (en) 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
DE60235955D1 (de) Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
WO2003002528A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
Pluta et al. The use of interferon in medicine
DE69836315D1 (de) Verwendung von TCF-II zur Behandlung von durch Krebs verursachtem Gewichtsverlust, Anaemie und TNF-Erhöhung
DE69817381D1 (de) Zusammensetzung und diese enthaltende pharmazeutische zubereitung für die behandlung von herpes und verwandten viralen infektionen
MA27187A1 (fr) Methodes et compositions pour le traitement de la toxicite gastro-intestinale provoquee par la therapie cytoablative
ATE210990T1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
CN106132983B (zh) 新型IFN-β蛋白类似物

Legal Events

Date Code Title Description
8364 No opposition during term of opposition